Citius’ first FDA decision date is approaching — and its CEO has millions on the line

It’s what biopharma CEOs dream of: winning an approval for a drug they’ve helped develop and delivering it to patients. With its PDUFA date slated for Aug. 13, Citius Pharmaceuticals is on that path with Lymphir, an immunotherapy for a rare blood cancer.